Characterizing the Immune Response and Neuronal Damage in COVID-19

Characterizing the Immune Response and Neuronal Damage in SARS-CoV-2 Infected Individuals

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04510012

Enrollment

Registered

2020-08-12

Start date

2020-03-05

Completion date

2021-01-30

Last updated

2023-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19, SARS-CoV Infection

Keywords

Innate immune response, Adaptive immune response, Inflammation, Neurological damage

Brief summary

The Investigators plan to study the innate and adaptive immune response, the inflammatory response, and associated complications such as complement activation and neurological damage in SARS-Cov-2 infected individuals. Patients with mild, moderate and severe COVID-19 disease will be enrolled.

Detailed description

The severity of coronavirus disease 2019 (COVID-19) ranges from asymptomatic infection to severe illness requiring mechanical ventilation. Immunological factors which lead to severe disease in certain COVID-19 patients remain incompletely understood. Neurological damage and complement activation may be a consequence of excess inflammation in severe COVID-19. The investigators plan to study the innate and adaptive immune response and potentially associated complications such as neurological damage and complement activation in mild, moderate and severe COVID-19 courses.

Interventions

OTHERAnalysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.

Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* PCR confirmed SARS-Cov-2 infection

Exclusion criteria

* Refusal to participate * Age \< 18 years

Design outcomes

Primary

Measure	Time frame	Description
Cytokine response to SARS-Cov-2	At enrollment	Measurement of cytokine concentration (pg/ml) in serum (IL-6, IL-8, IL-1b,TNF-alpha)
Innate immune response to SARS-Cov-2	At enrollment	Measurement of HLA-DR expression on CD14+ cells (flowcytometry)
Humoral immune response	At enrollment	Measurement of neutralizing SARS-Cov-2 antibody concentrations (plaque reduction assay)
Cell mediated immune response	At enrollment	Measurement of frequencies of SARS-Cov-2 specific T-cells (ELISPOT assay)
Neurological damage	At enrollment	Measurement of neurofilament light chains in serum (on ELLA platform; Protein Simple, Bio-techne)

Secondary

Measure	Time frame	Description
Complement activation	At enrollment	Measurement of factor B, factor H, factor I, C3a, C4a, C5a, SC5b9

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026